首页/数据集/Randomized Phase II Study of BSC vs Cetuximab vs Irinotecan and Cetuximab in Patients with KRAS codon G13D mutant Metastatic Colorectal Cancer (G13 study)

Randomized Phase II Study of BSC vs Cetuximab vs Irinotecan and Cetuximab in Patients with KRAS codon G13D mutant Metastatic Colorectal Cancer (G13 study)

NIAID Data Ecosystem2026-03-07 收录

结直肠癌精准治疗

KRAS突变研究

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2624252 数据链接链接失效反馈

官方服务：

资源简介：

Interventions: Cetuximab Cetuximab+Irinotecan BSC Primary outcome(s): Progression Free Survival Study Design: Parallel Randomized

应用场景：

创建时间：

2012-06-15

结直肠癌精准治疗

肿瘤基因组学分型

The goal of delivering the right drug to the right cancer patient (precision medicine) requires a detailed understanding of how genomic alterations are linked to drug response. The purpose of this stu

NIAID Data Ecosystem60

Generation of KRAS signatures using immortalized isogenic lung cells.

KRAS突变研究

肿瘤转录组学

We generated RNAseq profiles from Small Airway Epithelial Cells (SALE) expressing either KRAS G12V or GFP control. Overall design: SALE stably expressing with KRAS G12V or GFP were harvested two weeks

NIAID Data Ecosystem20

Supplementary Material for: Circulating tumor DNA testing overcomes limitations of comprehensive genomic profiling from tumor tissue

液体活检

结直肠癌精准治疗

The “liquid biopsy” is an established technique for examining circulating tumor DNA (ctDNA) from a routine blood draw and detecting actionable biomarkers. Nonetheless, ctDNA testing is rarely utilized

NIAID Data Ecosystem10

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

肿瘤药物临床试验

结直肠癌精准治疗

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.

NIAID Data Ecosystem60

RNA sequencing facilitates quantitative analysis of NPC cells, NPC-KRASG13D, and GSC cells (including U251-GSC, U118MG-GSC) transcriptomes. RNA sequencing facilitates quantitative analysis of NPC cells, NPC-KRASG13D, and GSC cells (including U251-GSC, U118MG-GSC) transcriptomes

基因表达调控

KRAS突变研究

To investigate the function of KRAS activation in the regulation of neoplastic features, we established NPC-KRASG13D cell lines in which KRAS has been overexpressed. We then performed gene expression

NIAID Data Ecosystem10

Randomized Phase II Study of BSC vs Cetuximab vs Irinotecan and Cetuximab in Patients with KRAS codon G13D mutant Metastatic Colorectal Cancer (G13 study)

资源简介：

相关数据集